Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj?gren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.

DOI:10.1016/S0140-6736(24)01211-X
作者：Benjamin A Fisher,?Xavier Mariette,?Athena Papas,?Thomas Grader-Beck,?Hendrika Bootsma,?Wan-Fai Ng,?P L A van Daele,?Stephanie Finzel,?Ghaith Noaiseh,?Sergio Elgueta,?Josef Hermann,?Sara S McCoy,?Esen
文献类型：期刊论文
补充材料：只需要正文